Review article
https://doi.org/10.21860/medflum2024_316208
Ceftazidime/ Avibactam for Treatment of Intrahospital Ventilator-Associated Pneumonia in COVID-19 Patients
Anja Mandarić
; KBC Zagreb, Klinika za anesteziologiju, reanimatologiju, intenzivnu medicinu i terapiju boli, Zagreb, Hrvatska
*
Ivan Šitum
; KBC Zagreb, Klinika za anesteziologiju, reanimatologiju, intenzivnu medicinu i terapiju boli, Zagreb, Hrvatska
Marko Siroglavić
; KBC Zagreb, Klinički zavod za kliničku mikrobiologiju, prevenciju i kontrolu infekcija, Zagreb, Hrvatska
Daniel Lovrić
; KBC Zagreb, Klinika za bolesti srca i krvnih žila, Zagreb, Hrvatska
Dora Karmelić
; KBC Zagreb, Klinika za anesteziologiju, reanimatologiju, intenzivnu medicinu i terapiju boli, Zagreb, Hrvatska
Ante Erceg
; KBC Zagreb, Klinika za anesteziologiju, reanimatologiju, intenzivnu medicinu i terapiju boli, Zagreb, Hrvatska
Mirabel Mažar
; KBC Zagreb, Klinika za anesteziologiju, reanimatologiju, intenzivnu medicinu i terapiju boli, Zagreb, Hrvatska
Slobodan Mihaljević
; KBC Zagreb, Klinika za anesteziologiju, reanimatologiju, intenzivnu medicinu i terapiju boli, Zagreb, Hrvatska
* Corresponding author.
Abstract
In the period of the coronavirus diseFase 2019 (COVID-19) pandemic, many patients requiring invasive mechanical ventilation were admitted to the intensive care unit (ICU) due to severe respiratory failure associated with COVID-19 infection. In fact, ICU admission and invasive ventilation increased the risk of ventilator-associated pneumonia (VAP), which is associated with a high mortality rate and longer ICU and hospital stays. Pseudomonas aeruginosa was the first causative agent of this pathology (VAP), but rare non-fermenting Gram-negative microorganisms such as Burkholderia cepacea and Stenotrophomonas maltophilia have also emerged as potential etiological agents. One of the most frequently used antibiotics against carbapenem- resistant Gram-negative microorganisms is ceftazidime/avibactam (CZA). The aim of this review article was to describe the use of CZA in a series of cases of patients with COVID-19 infection who developed difficult-to-treat VAP due to P. aeruginosa, B. cepacea and S. maltophilia and to compare it with data published in the literature, as well as to draw attention to the continuous administration of the drug as a different modality compared to the standard method of bolus administration. Despite the high mortality of critically ill patients with COVID-19, CZA, especially in combination therapy, could represent a valid treatment option for VAP caused by non-fermenting Gram-negative microorganisms.
Keywords
ceftazidime; COVID-19; pneumonia, ventilator-associated
Hrčak ID:
316208
URI
Publication date:
1.6.2024.
Visits: 782 *